By targeting tumor proliferation, limiting immune cell-mediated tumor support, and sensitizing tumors to standard treatments, Pyk2 inhibitors represent a compelling addition to the arsenal against GBM recurrence. The gene discussed is PTK2B; the disease is glioblastoma.